ClinicalTrials.gg
RecruitingNCT04285320Updated Nov 19, 2026

Antibiotic Bladder Instillations vs. Oral Suppression for the Treatment of Recurrent Urinary Tract Infections

A Phase 4 interventional study of Intravesical antibiotic instillation and Antibiotic oral suppressive therapy in Recurrent Urinary Tract Infection, sponsored by Atlantic Health System. Recruiting at 1 site in United States. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-19.

Sponsored by Atlantic Health System · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Jun 2021; still recruiting 5 years 5 months later.
Updated Nov 19, 2026Now RecruitingFirst site in United States+5 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
100
Allocation
Randomized
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 275 studies in Urinary Tract Infections with a site in United States — 44 open to participants now, 57 under way, 2 of them phase 3. Urinary Tract Infections · United States.

Planned enrollment
112th of 225
100 · median 100
Started
2021
with 11 others
Phase 4
40 of 275
10 open now
Primary completion
2027-06
later than 29 of 56 live
Registered
175th of 275
by date

Among the 275 studies in Urinary Tract Infections with a site in United States, this one is the 112th largest by planned enrollment of the 225 interventional ones that give a count, is one of 12 that started in 2021, is one of 40 in phase 4, reaches primary completion later than 29 of the 56 other live ones, and was the 175th registered.

Urinary Tract Infections

808 studies on the registry are indexed under Urinary Tract Infections; 135 are open to participants now.

Browse Urinary Tract Infections studies →

Open to participants now

44 of the 275 studies in Urinary Tract Infections with a site in United States are open now. Recruiting first, the newest first:

39 more — sign in →

All 44 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 84 Urinary Tract Infections studies recruiting now, 51 (61%) set no upper age limit and 23 (27%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 275 studies in Urinary Tract Infections with a site in United States, or all of them as a file.
02

Study summary

This is a research study that aims to determine if antibiotic bladder instillations (placing an antibiotic directly into the bladder) over several sessions at the office is a good option to prevent recurrent urinary tract infections, in comparison with oral suppression therapy (taking daily antibiotics in the form of pills by mouth). Oral antibiotic suppression therapy is currently the most common treatment route for recurrent urinary tract infections in post-menopausal women. The bladder antibiotic instillation may overcome the disadvantages of oral suppression therapy such as antibiotic resistance, certain side effects, and recurrence of infections after finishing the treatment course.

Read the detailed description

In this study, the investigators aim to determine the effectiveness of intra-vesical antibiotic instillations for the prophylactic treatment of recurrent urinary tract infections in menopausal women in comparison with oral suppressive therapy. This is a parallel un-blinded randomized-controlled trial. the investigators will randomize post-menopausal women with recurrent urinary tract infections to either receive 6-8 intra-vesical antibiotic instillations at the office or to receive 3 months of oral antibiotic suppressive therapy.

In the bladder instillation arm, based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol:

  • Amikacin-30 mg in 60 ml of sterile water
  • Gentamycin-80mg in 60ml sterile water
  • Tobramycin-80 mg in 100 ml of sterile water

In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile:

  • Trimethoprim daily (100 mg)
  • Trimethoprim/sulfamethoxazole daily (40 mg/200 mg)
  • Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg)
  • Nitrofurantoin monohydrate/macrocrystals daily (50 mg)
  • Nitrofurantoin monohydrate/macrocrystals daily (100 mg)
  • Cephalexin daily (125 mg)
  • Cephalexin daily (250 mg)
  • Fosfomycin every 10 days (3 grams) All medications used in this study are approved by the FDA to treat urinary tract infections.

Participants will be followed for total of 3 months after finishing either treatment course by only reviewing their medical records to collect data regarding development of urinary tract infections after treatment.

Primary endpoint/outcome:

  • To compare the number of women developing urinary tract infections during the 3 months following treatment between the two groups.

Secondary endpoints/outcomes:

  • To compare the rate of antibiotic resistance of isolated pathogens after intravesical antibiotic instillation vs. oral antibiotic suppressive therapy
  • To compare side effects of the two treatment modalities
03

Conditions studied

  • Recurrent Urinary Tract Infection

Keywords

  • Antibiotic bladder instillation
  • Intravesical antibiotic instillation
  • Oral suppressive therapy
  • Recurrent UTI
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • women with recurrent urinary tract infections (2 infections in a 6-month period or at least 3 infections in a 1-year period)
  • Receiving estrogen vaginal therapy for 1 month prior to enrollment
  • Able to come in to the office twice weekly for 3-4 weeks
  • English speaking
  • No allergy to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.
  • No uro-pathogen resistance to at least one of the three antibiotics used for bladder instillations and at least one of the four antibiotics recommended for oral suppressive therapy.

Exclusion criteria

Exclusion Criteria:

  • Allergy to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
  • Recent Urine culture with pathogens resistant to all study antibiotics (Gentamicin, Tobramycin, Amikacin, Trimethoprim/sulfamethoxazole, Fosfomycin, Nitrofurantoin and Cephalexin)
  • Renal failure ( \<30ml/min)
  • History of urinary retention
  • History of genitourinary structural abnormalities
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Active comparator
    Intravesical antibiotic instillation

    Drug: Intravesical antibiotic instillation

  • Active comparator
    Oral antibiotic suppressive therapy

    Drug: Antibiotic oral suppressive therapy

Interventions

  • DrugIntravesical antibiotic instillation

    Based on the participant's allergy and antibiotic resistance profile, one of the following three antibiotics will be instilled intravesically via a latex free BARD® 12 French Foley catheter for a total of 6-8 instillations (2 instillations/week) according to the Atlantic Health System Urogynecology Division antibiotic bladder instillation standard protocol: * Amikacin-30 mg in 60 ml of sterile water * Gentamycin-80mg in 60ml sterile water * Tobramycin-80 mg in 100 ml of sterile water

  • DrugAntibiotic oral suppressive therapy

    In the antibiotic oral suppression therapy arm, one of the following routinely used antibiotics will be prescribed for a total of 3 months according to the American Urogynecology Society Guidelines and based on the participant's allergy and antibiotic resistance profile: * Trimethoprim daily (100 mg) * Trimethoprim/sulfamethoxazole daily (40 mg/200 mg) * Trimethoprim/sulfamethoxazole every 3 days (40 mg/200 mg) * Nitrofurantoin monohydrate/macrocrystals daily (50 mg) * Nitrofurantoin monohydrate/macrocrystals daily (100 mg) * Cephalexin daily (125 mg) * Cephalexin daily (250 mg) * Fosfomycin every 10 days (3 grams)

06

What researchers measure

Primary outcomes

  1. The percentage of participants with urinary tract infections following treatment course

    To compare the percentage of women developing urinary tract infections during the 3 months following treatment between the two groups.

    Time frame: Assessed starting immediately after the treatment is completed for a total of 3 months.

Secondary outcomes

  1. The rate of antibiotic resistance of pathogens in participants developing urinary tract infections after completing the treatment course.

    To compare the rate of antibiotic resistance of isolated pathogens when participants develop a urinary tract infection during the 3 months follow up period after intra-vesical antibiotic instillation vs. oral antibiotic suppressive therapy. the percentage of antibiotics on the susceptibility list of urine cultures will be compared between participants developing urinary tract infection in each group during the 3 months follow-up period after completing the treatment.

    Time frame: Assessed starting immediately after the treatment is completed for a total of 3 months

  2. the percentage of patients developing side effects of the 2 treatments

    To compare the percentage of patients developing side effects between the two treatment modalities. At their routine follow up visits patients will be asked about whether or not they developed side effects and the type and severity of side effects of the treatment received. The percentage of patients developing side effects (per type and severity) in each arm will be compared.

    Time frame: From the date of randomization until the date of first documented side effect assessed up to 3 months after the treatment is completed in each arm

07

Study locations

1 of 1 sites recruiting
  • Atlantic Urogynecology Associates
    Morristown, New Jersey 07960, United States
    Recruiting
    • Dipensinh Solanki, MPH · Contact9739717361
    • Ricardo Caraballo, MD · Principal investigator
08

References and documents

Publications

  • Chernyak S, Salamon C. Intravesical Antibiotic Administration in the Treatment of Recurrent Urinary Tract Infections: Promising Results From a Case Series. Female Pelvic Med Reconstr Surg. 2020 Feb;26(2):152-154. doi: 10.1097/SPV.0000000000000810. PubMed 31990805 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2021 (actual). Primary completion is estimated for Jun 2027, 72 months after the start.

Of 45 non-industry phase 4 interventional studies under Urinary Tract Infections, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 54. This study's planned 72 months is above that.

Counting every sponsor, half of 51 studies reached it within 37 months; a quarter within 22 and three quarters within 50.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 19, 2026: start Mar 2021 → Jun 2021, primary completion Apr 2023 → Jun 2027 and completion Apr 2023 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 17, 2020
First posted
Feb 26, 2020
StartActual
Jun 11, 2021was Mar 2021
Primary completionEst.
Jun 2027was Apr 2023
CompletionEst.
Dec 2027was Apr 2023
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Status unknown→Recruiting
changed Nov 19, 2026
Sites
1 site added — first site in United States
Show site
  • Atlantic Urogynecology Associates · Morristown, United States
Nov 19, 2026
Start date
Mar 2021→Jun 11, 2021 (actual)
Nov 19, 2026
Primary completion
Apr 2023→Jun 2027
Nov 19, 2026
Study completion
Apr 2023→Dec 2027
Nov 19, 2026
Contact
Study contact changed: c•••@atlantichealth.org · •••7361→D•••@atlantichealth.org · •••7361. See the current contact
Nov 19, 2026
Show all 1 update
  1. Nov 19, 2026
    Status unknown→Recruiting
    1 site added — first site in United States
    Show site
    • Atlantic Urogynecology Associates · Morristown, United States
    Start date Mar 2021→Jun 11, 2021 (now actual)
    Primary completion Apr 2023→Jun 2027
    Study completion Apr 2023→Dec 2027
    Contact Study contact changed: c•••@atlantichealth.org · •••7361→D•••@atlantichealth.org · •••7361. See the current contact
    + 3 other changes: verification date, responsible party and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT04285320
Lead sponsor
Atlantic Health System
Responsible party
Shaun Adair (Urogynecology & Pelvic Reconstructive Surgeon, Atlantic Health System) — Principal investigator
First posted
Feb 26, 2020
Start date
Jun 11, 2021
Primary completion
Jun 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 19, 2026

Study contacts

Dipensinh Solanki, MPH
Contact
Dipensinh.solanki@atlantichealth.org
973-971-7361
Ricardo Caraballo, MD
principal investigator · Atlantic Health System - Morristown Medical Center

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion